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Historically, breast cancer rates in Asia are one-sixth of the rates of
Whites in the USA. Corresponding to the lower breast cancer rates
in Asia, endogenous oestradiol levels are also lower among native
Asians compared to White women in the USA or UK (Wu and
Pike, 1995). Reasons for the lower endogenous oestradiol levels
and lower breast cancer rates in Asians are not known. One
hypothesis is that the traditionally high intake of soy in Asia, the
main source of isoflavones (one of two main classes of phyto-
oestrogens in the human diet), may explain in part the lower breast
cancer rates and oestrogen levels (Adlercreutz, 1990; Messina and
Barnes, 1991). The mechanisms by which soy influences risk of
breast cancer are not known. A predominant hypothesis focuses on
the potential effects of soy on hormone production and metabo-
lism. There is currently only circumstantial evidence in support of
this hypothesis. A small cross-sectional study of premenopausal
women in Japan reported an inverse association between intake of
soy foods and serum oestradiol levels (Nagata et al, 1997). Two
(Lu et al, 1996; Nagata et al, 1998) of five (Cassidy et al, 1994;
Lu et al, 1996; Petrakis et al, 1996; Nagata et al, 1998; Duncan
et al, 1999) soy intervention studies in premenopausal women
found a substantial reduction in serum oestradiol levels in associa-
tion with soy supplementation. Both ‘positive’ studies (Lu et al,
1996; Nagata et al, 1998) used soy foods (instead of soy protein or
isolates) and higher amounts of isoflavones than the other studies
(Duncan et al (1999) used two doses; the higher dose was compa-
rable to that used in Nagata et al (1998)). We designed a study
to further investigate the effects of soy on ovarian function in
premenopausal women using traditional Asian soy foods, as the
protective effect observed in epidemiologic studies is based on
populations consuming soy foods (not soy protein or isolates). As
part of the study design, we also collected daily morning urine
specimens during the entire study in order that the dates of ovula-
tion (based on peak levels of urinary luteinizing hormone (LH))
could be accurately estimated. Knowledge of the day of ovulation
allowed us to evaluate hormonal responses to soy supplementation
after standardization for the day of blood specimen collection.
SUBJECTS AND METHODS
Study subjects and data collection
Study participants were employees at the Health Sciences Campus
at the University of Southern California. We advertised the study
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urinary luteinizing hormone (LH) peak was used as a marker for the day of ovulation. Knowledge of day of ovulation allowed comparison of
hormone measurements at baseline to those obtained during intervention and recovery cycles with standardization of day of cycle. Soy
intervention was associated with a statistically significant reduction in serum luteal oestradiol level (–9.3%, P < 0.05), but there were no
significant changes in follicular phase oestradiol, follicular or luteal phase progesterone, sex hormone-binding globulin or menstrual cycle
length. This significant reduction in luteal phase oestradiol was, however, observed only among Asian (–17.4%) but not among non-Asian
(–1.2%) participants; urinary excretion of isoflavones was higher among Asians than non-Asians (29.2 vs 17.1 mmol day–1, P = 0.16) during
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different race/ethnicities and using both traditional soy foods and soy protein products providing comparable doses of isoflavones are needed
to definitively determine the effect of soy on ovarian function. © 2000 Cancer Research Campaign
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tives of the study and requirements for participation. Interested
subjects completed a brief questionnaire that included information
on demographic and selected lifestyle characteristics. Exclusion
criteria included current or recent (within the last 12 months) preg-
nancy or lactation, irregular menstrual cycles, current use of oral
or other hormonal contraceptives or hormones, history of chronic
illness (e.g. diabetes) or cancer, current smoker and following a
special diet. Twenty women completed the study of at least seven
menstrual cycles in a free-living environment.
The study protocol was approved by the University of Southern
California Institutional Review Board Human Subjects
Committee. The study consisted of a baseline period of two
menstrual cycles, a soy intervention period of three cycles and a
‘recovery’ period of at least two cycles (eight of the 20 women
completed an 8th month, i.e. had three recovery cycles).
Throughout the duration of the study, participants were asked to
consume their usual diets with added instructions to avoid intake
of soy products during the baseline and recovery periods. During
the soy intervention period, their usual diets were supplemented
with three traditional Asian soy foods (tofu, soymilk and frozen
soybeans peas (edamame)) purchased by the investigators.
Subjects were instructed to consume 161 g of Mori-Nu Silken
Extra Firm tofu or 322 g of Eden soymilk or 75 g of Kimbo frozen
soybean peas per day; these amounts of the three foods contained
equivalent amounts of isoflavones. On the basis of published soy
food isoflavone levels (Coward et al, 1993), subjects were
permitted to consume any combination of the three foods that
provided an equivalent amount of isoflavone. The soy diet
commenced on day 1 of the third menstrual cycle and ended on
day 1 of the sixth menstrual cycle.
At study entry, subjects completed a questionnaire that asked
about menstrual and reproductive history. During the study,
subjects completed a daily log which itemized consumption of
alcoholic beverages, duration of physical exercise and consump-
tion of any soy products during the months when they were
supposed to abstain from these foods. In addition, a daily ‘soy’ log
was used to record the specific soy food and amount consumed
during the soy intervention cycles. Four times during each
menstrual cycle (typically one recall per week), a 24-h diet recall
was completed. Average intakes of energy, total and components
of fat, protein, carbohydrate, cholesterol, dietary fibre and other
micronutrients were calculated for each menstrual cycle (food
records were analysed at the Nutrition Service Core at the
University of Hawaii).
Overnight daily voids were collected from participants during
the study. Urine specimens were collected in plastic containers
containing 1 g of ascorbic acid. Subjects were instructed to void
prior to sleep and collect all subsequent voids including the first
morning one. The period of urine collection was at least 4 h.
A 100-ml aliquot of each urine specimen was taken for the study
and the remainder was discarded. The 100-ml aliquot was sub-
divided into 6 portions of 15–20 ml and stored at –20°C.
Creatinine (CR) was measured in all urine samples to standardize
LH and isoflavone values. Blood specimens were obtained on two
occasions (days 10–12 and days 20–22) of each menstrual cycle,
allowed to clot and the serum was stored at –70°C. In the event
that menstrual cycles exceeded 28 days, blood specimens were
also collected on days 29, 36 and 43 (if applicable). Once per
month at the time of blood collection, body weight and hip and
waist measurements were obtained.
Analysis of isoflavone levels in foods and urines
The same brand of soy foods was purchased and used during the
entire study. The total isoflavone levels (all 12 isomers of
daidzein, genistein, glycitein) in the soy foods (Mori-Nu Silken
Extra Firm tofu, Kimbo frozen soybean peas, and Eden soymilk)
were determined by one of us (PM) nine times during the study to
assess variability in the amount of isoflavones in these foods. Four
random urine samples (about one sample per week) per cycle were
selected and tested for urinary isoflavone levels to determine
compliance during the soy intervention period and avoidance of
these foods during baseline and recovery (urinary isoflavone
analysis was conducted by Drs Patricia Murphy and Suzanne
Hendrich, Iowa State University). To determine both food and
urinary isoflavone levels, we used a high-performance liquid
chromatography (HPLC) quantitation method, developed by
these investigators which hydrolyses isoflavone metabolites and
extracts and quantifies isoflavone aglycones (Wang and Murphy,
1994; Xu et al, 1994; Murphy et al, 1997).
Measurement of serum and urinary hormones
Hormone analyses were conducted by Dr Frank Z Stanczyk at the
University of Southern California. Total oestradiol and proges-
terone were measured in serum by validated specific
radioimmunoassay (RIA) methods following extraction (Scott
et al, 1978; Stanczyk et al, 1988). Urinary LH was measured by an
immunoradiometric assay using the LH MAIA clone kit (Biodata
Diagnostics, Rome, Italy). SHBG was quantified by RIA utilizing
a commercial kit obtained from Diagnostics Systems Laboratories
(Webster, TX, USA). Because the objective of this study was to
test for differences in hormone profiles within individuals, the
urinary and serum hormone measurements for each participant
was performed in the same assay to reduce inter-assay variability.
Urinary creatinine (CR) levels were measured colorimetrically.
Cholesterol and triglyceride measurements were conducted by a
commercial laboratory (Endocrine Sciences, Calabasas Hills, CA,
USA).
Statistical analysis
Daily urinary isoflavone excretion
Individual urinary isoflavone measurements were transformed
logarithmically to achieve approximate normal distributions. We
calculated the daily urine isoflavone excretion as (isoflavone
concentration/CR concentration) ´ 1.2 g, where 1.2 g is the
assumed daily creatinine excretion (Krupps et al, 1982).
Standardization of hormone values
Our approach to ‘adjustment’ for day of the cycle was to calculate
‘standardized’ hormone values as follows. We first identified the
day when the urinary LH/CR level was a clear maximum and
assumed that day of ovulation was 1 day after this peak. The
follicular phase was defined as day 1 of the menstrual cycle
through the day of the LH/CR peak, and the luteal phase was
defined as the remainder of the cycle through the last day before
the start of the next menses. Based on the ‘ovulation’ day (day 0)
for a specific subject and menstrual cycle, each blood specimen
was assigned a ‘true’ specimen collection day relative to ovulation
(i.e. days –1, –2, –3, –4, etc. were assigned to specimens collected
prior to the day of ovulation, and days 0, +1, +2, +3, +4, etc. for
those collected at or after the day of ovulation).
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rately for progesterone and SHBG) by calculating the geometric
mean of oestradiol values for each specific day of the menstrual
cycle (as defined above) utilizing all of the specimens collected.
(Geometric mean values were calculated rather than mean values
because of the well-known skewed distribution of oestradiol
values.) ‘Adjusted’ oestradiol values were then calculated as the
ratio of the measured oestradiol values to the values of this
standard curve at the same day of the cycle. Adjusted hormone
measurements were transformed logarithmically to achieve
approximate normal distributions.
To evaluate whether serum hormone levels change in associa-
tion with soy intervention, t-tests and analysis of variance
(ANOVA) were conducted to compare the averaged log standard-
ized ratios during baseline months to that obtained during inter-
vention and recovery months. Results shown in the tables are
obtained by taking the exponential of the average difference in log
standardized hormone levels between the study periods of interest.
A total of seven menstrual cycles (three intervention and four
recovery months) were excluded from data analysis because urine
specimens were unavailable for more than 3 days between days 10
and 22 of the menstrual cycle, and the LH peak could not be
determined with confidence. Results are shown for analyses that
included a total of 147 menstrual cycles (40 baseline, 57 interven-
tion and 50 recovery). There were 13 other menstrual cycles (three
baseline, seven intervention and three recovery) in which luteal
serum progesterone levels were below 3.0 ng ml–1 (a presumptive
marker of ovulation) (Israel et al, 1972) (range 0.35–2.76). Seven
of these 13 specimens were collected 3 days after ovulation and
three others were collected more than 10 days after ovulation.
Thus, the low progesterone levels of most of these samples may be
related to the collection of samples either too soon or too late after
ovulation. We repeated all analyses after exclusion of these 13
menstrual cycles (referred to as the ‘clean’ analysis which
included data on 134 menstrual cycles (37 baseline, 50 interven-
tion and 47 recovery)).
RESULTS
The mean age of the 20 study participants was 34.1 ± 7.4 years
(range 21–44). An equal number of parous and nulliparous women
(mean ages were 37.3 and 30.9 respectively) and an equal number
of Asian and non-Asian (mean ages were 35.6 and 32.6 respec-
tively) participants were included. (Asians included six Chinese,
one Japanese, two Vietnamese and one Filipino; and non-Asians
included six whites and four Latinas.) There were only very slight
changes in body measurements during the study period in all
subjects combined, or separately in Asians and non-Asians
(Table 1, data for circumferences of waist and hip and weight not
shown). Similarly, there were no significant changes in total serum
cholesterol or any of the lipid fractions during the study period
(Table 1). Intake of energy, fat, protein, carbohydrates (both
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Table 1 Body mass index, serum lipid profile and dietary intake (mean ± s.d.)
Subjects Baseline Intervention Recovery
Body size All 23.1 ± 3.3 23.6 ± 3.5 23.7 ± 3.5
BMI (kg m–2) Asians 22.7 ± 4.1 23.1 ± 4.3 23.1 ± 4.4
Non-Asians 23.6 ± 2.4 24.2 ± 2.5 24.4 ± 2.5
Serum levels (mg dL–1
Total cholesterol All 169.6 ± 30.0 169.1 ± 26.7 170.7 ± 26.6
Asians 162.5 ± 30.7 161.9 ± 28.3 162.4 ± 26.4
Non-Asians 176.7 ± 29.0 176.1 ± 24.3 179.0 ± 25.4
HDL cholesterol All 59.8 ± 15.0 59.7 ± 13.3 60.5 ± 13.0
Asians 52.8 ± 10.9 53.6 ± 9.2 53.2 ± 8.9
Non-Asians 66.7 ± 15.8 65.6 ± 14.3 67.6 ± 12.6
LDL cholesterol All 92.3 ± 39.1 91.4 ± 40.0 90.1 ± 36.9
Asians 96.9 ± 50.8 92.1 ± 50.3 95.3 ± 45.1
Non-Asians 87.6 ± 24.6 90.3 ± 29.6 84.7 ± 28.1
Triglycerides All 86.3 ± 26.8 85.8 ± 23.9 87.7 ± 22.9
Asians 88.5 ± 30.6 87.3 ± 28.8 84.9 ± 27.1
Non-Asians 84.1 ± 23.8 84.1 ± 19.2 90.6 ± 18.8
Daily diet
% calories from fat All 33.2 ± 6.5 33.0 ± 4.8 33.4 ± 6.5
Asians 31.4 ± 6.4 32.7 ± 4.5 32.5 ± 4.8
Non-Asians 35.0 ± 6.3 33.3 ± 5.3 34.4 ± 8.1
% calories from All 15.9 ± 2.3 16.7 ± 2.4 16.0 ± 2.3
protein Asians 16.6 ± 2.7 17.5 ± 3.0 15.8 ± 2.8
Non-Asians 15.3 ± 1.8 15.9 ± 1.5 16.3 ± 1.8
% calories from All 51.0 ± 7.8 50.5 ± 5.0 50.8 ± 6.3
carbohydrates Asians 52.7 ± 7.5 50.1 ± 5.3 52.1 ± 6.1
Non-Asians 49.3 ± 8.2 50.8 ± 4.8 49.3 ± 6.5
Dietary cholesterol All 248.9 ± 130.1 236.3 ± 131.9 223.6 ± 121.1
(mg) Asians 300.7 ± 132.4 281.2 ± 140.7 244.3 ± 123.3
Non-Asians 197.0 ± 107.6 184.2 ± 100.3 193.2 ± 94.1
Dietary fibre (g) All 16.2 ± 4.3 18.6 ± 6.6 14.5 ± 5.1
Asians 17.4 ± 3.8 19.2 ± 6.8 14.6 ± 5.2
Non-Asians 15.0 ± 4.5 17.8 ± 6.4 14.3 ± 5.1absolute intakes and as per cent of calories), fibre and various
micronutrients, based on dietary recalls, also did not change
significantly during the study period (Table 1).
On a per gram basis (wet weight), the total isoflavone (all 12
isomers of daidzein, genistein and glycitein) content found in our
test foods was as follows: highest in tofu (0.247 mg g–1), inter-
mediate in soybean peas (0.197 mg g–1) and lowest in soymilk
(0.075 mg g–1). On the basis of these results, the isoflavone content
of 1 g of tofu is approximately equivalent to 1.2 g of soybeans or
3.3 g of soymilk. Using these isoflavone content values, we
calculated that the mean daily isoflavone intake among study
participants during the intervention months was 32.0 ± 10.5 mg
(36.2  ± 12.0 mg in Asians, and 27.7 ± 7.0 mg in non-Asians,
P = 0.07).
Each specific urinary isoflavone (daidzein, genistein, glycitein)
and total isoflavone/CR increased significantly (P < 0.001) during
soy intervention compared to baseline levels; this increase was
observed in both Asians and non-Asians (Table 2 shows data for
total isoflavones). Although baseline urinary isoflavone excretions
did not differ between Asian and non-Asian participants (they
were low for both groups), levels of the individual and total
isoflavones were significantly higher among Asian compared to
non-Asian participants during the intervention period (32.1 vs
12.8 mmol day–1) (P = 0.04). The difference in urinary isoflavone
levels between Asians and non-Asians diminished after adjust-
ment for isoflavone intake (29.2 ± vs 17.1 mmol day–1, P = 0.16).
During the intervention period, the sources of isoflavones did not
differ between the two groups. Soymilk, tofu and soybeans
accounted for 46%, 50% and 4% respectively, of soy intake among
Asian participants; the corresponding figures were 50%, 46% and
4% among non-Asian participants. Urinary isoflavone levels
returned almost to baseline levels during the recovery months but
they remained higher in Asian compared to non-Asian participants
during the recovery period.
Cycle length did not change during the study period. The
average cycle length was 29.2 ± 3.4 days during baseline,
29.3  ± 3.8 days during intervention and 29.5 ± 5.6 days during
recovery. Both follicular and luteal phase length remained
unchanged: the mean follicular phase length was 16.5, 16.7 and
17.3 days respectively, while the corresponding luteal phase length
was 12.7, 12.5 and 12.2 days. The peak urinary LH level and the
average follicular and luteal phase LH levels were not signifi-
cantly different during intervention compared to baseline levels
(data not shown). Results for cycle length and urinary LH were
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Table 2 Mean daily urinary excretion of total isoflavones/creatinine a(mmol day–1)
Subjects Baseline* Intervention* Recovery
Mean ± s.e. Mean ± s.e. Mean ± s.e.
All 0.34 ± 1.17 20.28 ± 1.26b 2.69 ± 0.56
Asians 0.31 ± 1.28 32.07 ± 1.27† 3.87 ± 0.66†
Non-Asians 0.36 ± 1.22 12.81 ± 1.42† 1.52 ± 0.27†
aGeometric means of total urinary isoflavone (daidzein, genistein, glycetein)/creatinine are
shown. bGeometric means of daidzein, genistein, glycetein (divided by creatinine) were 11.34,
6.39 and 1.27 respectively for all subjects combined; the corresponding levels were 17.00, 11.65
and 1.66 in Asian participants, and 7.56, 3.50 and 0.97 in non-Asian participants. *P < 0.05 for
difference in total urinary isoflavones/creatinine between baseline and intervention levels, for all
subjects combined and separately in Asians and non-Asians. †P < 0.05 for difference in total
urinary isoflavones/creatinine between Asians and non-Asians for the specific study period.
Table 3 Serum estradiol, progesterone and sex hormone-binding globulin levels during intervention and recovery months relative to baseline levels
Intervention/ Recovery/
Hormone Subjects Baseline (%) P-value Baseline P-value
(%)
Follicular oestradiol All 99.3 0.92 90.5 0.32
Asians 92.6 0.40 89.4 0.39
Non-Asians 106.0 0.54 91.4 0.58
Luteal oestradiol All 90.7 0.05 93.2 0.43
Asians 82.6 0.005 97.6 0.79
Non-Asians 98.8 0.87 88.8 0.47
Follicular progesterone All 99.4 0.96 106.4 0.55
Asians 96.5 0.84 101.5 0.94
Non-Asians 102.4 0.79 110.7 0.31
Luteal progesterone All 86.1 0.43 71.9 0.20
Asians 81.2 0.33 77.4 0.17
Non-Asians 90.9 0.77 66.3 0.43
Follicular SHBG All 98.5 0.80 98.1 0.78
Asians 85.1 0.08 94.9 0.68
Non-Asians 118.0 0.009 101.0 0.89
Luteal SHBG All 98.0 0.75 94.3 0.38
Asians 87.7 0.18 94.9 0.68
Non-Asians 116.4 0.05 96.6 0.65similar in Asians and non-Asians, and were comparable when we
repeated the analysis restricted to the ‘clean’ dataset. Changes in
serum oestradiol, progesterone and SHBG levels during the study
are shown in Table 3. In all subjects combined, luteal phase
oestradiol levels were reduced statistically significantly (–9.3%,
P = 0.05) during soy intervention compared to baseline oestradiol
level, but this was not observed for follicular phase oestradiol
levels (–0.7%, P = 0.92). Luteal phase progesterone levels were
also lower while SHBG levels were similar to baseline levels;
none of these differences were statistically significant. Levels of
oestradiol, progesterone and SHBG during recovery months did
not differ significantly from baseline levels. Results were similar
when we repeated the analyses restricted to the ‘clean’ dataset
although the reduction in luteal phase oestradiol levels was
reduced slightly (–8.9%, P = 0.06).
Although not in the original study design, we conducted ethnic-
specific analysis because of the higher urinary excretion of
isoflavones during intervention among Asians. Among Asian
Ovarian function and soy foods in premenopausal women 1883
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Table 4 Summary of soy dietary intervention and serum hormone response in premenopausal women. Published studies are ordered by increasing dose of
soy (mg of isoflavones per day) added during the intervention period
Study Blood specimen Cycle length Estradiol Pg SHBG LH
collection (intervention vs (intervention (intervention (intervention (intervention
baseline) vs baseline) vs baseline) vs baseline) vs baseline)
Cassidy et al, 1994a Bloods every 3 T: ­ 5.4% F: ­ 47.2% L: ¯ 14% T: ¯ 2.6% M: ¯ 66.5%
(1) 6 women in 1994 days – early F: ­ 16.7% L: no change F: ¯ 1.8%
(2) 1 month morning L: ¯ 8% M: ­ 9.9% L: ¯ 5.2%
(3) soy protein
(4) 45 mg isoflavones day–1
(5) 12.8 mmol day–1
Petrakis et al, 1996 Variable NA T: ­ 18% T: ¯ 41% T: ¯ 36% NA
(1) 14 women
(2) 6 months
(3) soy protein isolate
(4) 74 mg isoflavones day–1
(5) 69.8 mmol day–1
Duncan et al, 1999 Bloods every LS vs C LS vs C LS vs C LS vs C LS vs C
(1) 14 women other day T: ­ 2.1% MF: ­ 9.0% MF: ­ 22.4% No change MF: ­ 1%
(2) 3 cycles + 9 days beginning 7 days MF: ­ 3.6% ML: ¯ 6.4% ML: ¯ 16.8% ML: ¯ 4.0%
(3) soy protein powder, after LH surge in ML: no change
@ 3 doses menstrual cycle 2
(4) control [C] = 10 mg isof day–1 until end of diet HS vs C HS vs C HS vs C HS vs C HS vs C
low soy [LS] = 64 mg isof day–1 period T: ­ 1.4% MF: ­ 5.0% MF: ¯ 3.9% No change MF: ¯ 5.6%
hi soy [HS] = 128 mg isof day–1 MF: ¯ 3.6% ML: no change ML: ¯ 12.6% ML: ­ 8.8%
(5) [C] = 4.9 mmol day–1 ML: ­ 5.5%
[LS] = 23.4 mmol day–1
[HS] = 49.8 mmol day–1
Nagata et al, 1998 Morning bloods Entire group Entire group NA Entire group NA
(1) 31 women on soy [S], on day 11 of [C]: ¯ 2.7% [C]: ­ 3.9% [C]: ­ 3.5%
29 on control diet [C] cycles 1 and 3 [S]: ­ 4.3% [S]: ¯ 27.3% [S]: no change
(2) 2 months
(3) soymilk Subgroupb Subgroupb Subgroupb
(4) 109 mg isofl day–1 for [S]; [C]: ¯ 1.7% [C]:­ 10.4% [C]: ­ 2.0%
18 gm isofl day–1 for [C] [S]: ­ 5.1% [S]: ¯ 33.3% [S]: ¯ 3.4%
(5) NA
Lu et al, 1996 Blood samples T: ­ 12.4% T: ¯ 62% T: ¯ 35% NA NA
(1) 6 women before and 1 day LF: ¯ 81%
(2) 1 month after starting L: ¯ 49%
(3) soymilk soymilk, at
(4) 216 mg isofl day–1 weekly intervals
(5) NA during soy
feeding
Wu et al (current study) Bloods on days T: no change F: no change F: no change F: ­ 1.5% NA
(1) 20 women 10–12 and 20–22, F: no change L: ¯ 9.3% L: ¯ 13.9% L: ­ 2.0%
(2) 3 months every cycle L: no change
(3) tofu, soymilk, soybean
(4) 32 mg isofl day–1
(5) 20.3 mmol day–1
aThese investigators reported in a letter (Setchell et al, 1995) that when results from three additional women were combined with those of the six subjects in
Cassidy et al (1994), the increase in follicular phase plasma oestradiol levels in association with soy supplementation was smaller (­ 16%) and was not
statistically significant. bSubgroup included only women from whom blood samples were obtained on the same day or 1 day apart of the menstrual cycles 1 and
3. (1) Subjectsa; (2) duration of soy feeding; (3) type of soyfood; (4) isoflavones (mg day–1) during feeding; (5) urinary isoflavones (mmol day–1) during feeding.
T = total cycle; F = Follicular; l = Luteal; M = mid cycle; MF = midfollicular; ML = midluteal; LF = late follicularparticipants, both follicular (–7.4%) and luteal phase oestradiol
(–17.4%) decreased in association with soy supplementation,
although only the change during the luteal phase was statistically
significant (Table 3). Among non-Asian participants, there were
no reductions in serum oestradiol levels but there were statistically
significant increases in both follicular and luteal phase SHBG
levels (Table 3). Results were unchanged when we restricted the
analysis to the ‘clean’ dataset. Urinary excretion of isoflavone was
not, however, correlated with the difference in serum luteal oestra-
diol in all subjects combined (P = 0.66) or separately in Asian
(P = 0.84) and non-Asian (P = 0.95) participants.
DISCUSSION
Intake of soy (in isoflavone units) in Asia was first reported to be
around 150–200 mg per day (Cassidy et al, 1994). However,
studies which provided details regarding the amounts of specific
types of soy foods consumed and their corresponding isoflavone
levels found a much lower intake in Japan and China, between 15
and 40 mg of isoflavones per day (Nagata et al, 1998; Chen et al,
1999; Wakai et al, 1999). The higher values initially reported
appear to have been based on the assumption that soy foods
contain 2–3 mg of isoflavones per gram, when these levels apply
primarily to whole soybeans, a form of soy food not very
commonly consumed in Asia (Adlercreutz et al, 1991; Nagata
et al, 1998; Chen et al, 1999; Wakai et al, 1999). Recent studies
(Franke et al, 1999; Murphy et al, 1999) confirmed that commonly
consumed Asian soy foods (e.g. soymilk, tofu, miso) contain
substantially lower isoflavone levels (0.10–0.35 mg g–1) than
whole soybeans; these values also tend to be lower than previously
published values. Failure to normalize for molecular weight differ-
ences of the isoflavone isomers (Franke et al, 1999; Murphy et al,
1999) and inadequate accounting for moisture factor may explain
in part higher isoflavone values. The average amount of
isoflavones (32.0 mg day–1) consumed by participants in our study
during the intervention period is within the range of current
isoflavone intake in Asia (Nagata et al, 1998; Chen et al, 1999;
Wakai et al, 1999).
Soy may reduce the risk of breast cancer by affecting ovarian
function, specifically endogenous oestrogen levels. This study
provided some support that soy supplementation in the amount of
about 30 mg of isoflavones per day over 3 months is associated
with a statistically significant 9% reduction in luteal phase oestra-
diol. This reduction in serum oestradiol was confined to Asian
participants who consumed more soy isoflavones (mean daily
intake was 9 mg of isoflavones higher than non-Asians) and
excreted higher isoflavone levels during intervention than non-
Asian participants. However, it is not clear that this difference in
reported soy intake contributed to the difference in hormone
response, as there was no significant correlation between changes
in serum oestradiol levels and urinary isoflavone levels in all
subjects combined or separately in Asians and non-Asians. Only a
larger study designed specifically to evaluate possible ethnic
differences in hormonal response can resolve this question.
Table 4 summarizes the five published soy intervention studies
in premenopausal women, showing differences in study design,
including the type of soy products used, the amount of isoflavones
added (range 45–216 mg) and the duration of supplementation.
One was conducted among native Japanese and the other four
were conducted presumably among non-Asians in the USA or the
UK. Serum oestradiol was measured in all five studies, whereas
progesterone, SHBG, LH and cycle length were measured in only
some studies. The manner in which changes in ovarian function
(i.e. timing and frequency of blood specimen collection) were
monitored also varied.
Two studies, using soymilk in the amounts of 109 (Nagata et al,
1998) and 216 mg of isoflavones daily (Lu et al, 1996) provided
strong support that soy supplementation may reduce serum oestra-
diol levels. However, given that isoflavone levels vary substan-
tially in soymilk (even within a single brand) (Murphy et al, 1999)
and it is unclear that the isoflavone content was monitored in these
studies, we are less certain of the actual isoflavone intake. No
significant reduction in serum oestradiol levels was found in all
three studies which used soy protein or isolates (range 45–129 mg
of isoflavones per day) (Table 4). One study measured both serum
and urinary oestrogen levels; serum oestradiol levels did not
change significantly (Duncan et al, 1999) but urinary excretion of
oestrogens and the hypothesized genotoxic oestrogen metabolites
(Xu et al, 1998) decreased significantly in association with soy
supplementation. Reasons for the differences in blood and urinary
oestrogen findings in this study are not apparent.
Interpretation of the current results is hampered by our lack of
understanding of the relative importance of the source of and the
amount of soy isoflavones and role of race/ethnicity in hormonal
response. Isoflavone may not be the ‘active’ ingredient in soy
foods or there may be other constituents (e.g. saponins, protease
inhibitors) that are also important. While there are undisputed
East–West differences in the consumption of soy foods and the
epidemiologic evidence on cancer risk is based on soy foods (not
soy ingredient), the majority of soy intervention studies have used
soy ingredients because of greater ease in use and acceptance. One
soy intervention study included both soy foods and soy ingredients
as test foods (Cassidy et al, 1995); but because of the high salt
content of miso (the soy food used), only three subjects completed
this diet. Thus, there are no data from intervention studies that
have used both soy foods and soy ingredients as test foods to
assess whether the sources of isoflavones and/or differences in the
amount of isoflavones or other factors are relevant. It will be
important to design intervention studies that include both soy
foods and soy ingredients in the same study and in which compar-
able amounts of isoflavones are added. In addition, it is important
to measure isoflavone levels in the test soy foods to determine the
actual amount of isoflavones consumed.
While it is reasonable to presume that the amount of isoflavones
would matter, the optimal dose to use in intervention studies is not
known. The almost fivefold range in the amount of isoflavones
used in the published intervention studies may also contribute to
the differences in study results.
Isoflavone bioavailability is known to depend on the relative
degradation ability of gut microflora. The ingested isoflavones in
soy foods are largely in the form of glycosides that are poorly
absorbed in the small intestine compared with their aglycones
because of their larger molecular weight and higher hydrophilicity
(Brown, 1988). Glucosidases of intestinal microflora in the large
intestine can hydrolyse the isoflavone glycosides to produce
aglycones and promote their absorption. Deconjugating enzymes
(i.e.  b-glucuronidases and arylsulfatases) may also influence
isoflavone bioavailability (Xu et al, 1995). Race/ethnicity may be
associated with genetic variability in bacteria flora and/or differ-
ences in dietary habits (e.g. fat and fibre intake) which may influ-
ence the concentration of microfloral enzymes (Adlercreutz et al,
1992; Goldin and Gorbach, 1994; Xu et al, 1994; Tew et al, 1996;
1884 AH Wu et al
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compounds. For example, faecal bacterial b-glucuronidase activity
has been found to increase in association with high dietary fat
intake and to decrease in association with high dietary fibre intake
(Goldin and Gorbach, 1994).
In this study, cycle length did not change in association with soy
supplementation, whereas statistically significant increases of
5–12% have been reported (Cassidy et al, 1994; Lu et al, 1996;
Nagata et al, 1998) (Table 4). Serum luteal or total progesterone
levels decreased consistently in this and previous studies
(13–41%) although this reduction did not reach statistical signifi-
cance (Table 4). Serum SHBG decreased among Asian but
increased statistically significantly among non-Asian participants
in this study. There are no consistent changes in serum SHBG in
previous studies (Table 4). Of previous studies that measured
serum LH levels, a statistically significant reduction in levels was
found in one (Cassidy et al, 1994). Urinary LH decreased
nonsignificantly in association with soy intervention in this study
(serum LH was not measured). Consumption of soy protein has
been associated with significant reductions in total and LDL
cholesterol and triglycerides, but the effect of soy on cholesterol
levels may depend on the initial levels prior to intervention
(Anderson et al, 1995). Serum lipid levels were normal to low in
our participants; this may explain the absence of significant
changes in lipid profile in this study.
Variation also exists in the monitoring of changes in hormone
levels from one cycle to the next (Table 4). Unless daily or nearly
daily blood specimens can be collected, it is difficult to be certain
that comparisons of hormone levels between cycles are made on
specimens collected from comparable days cycle to cycle. Our
ability to identify day of LH peak as a marker of ovulation for over
90% of the menstrual cycles collected has enabled us to accurately
determine day when specimens were collected relative to day of
ovulation and to compare changes in each cycle with standardiza-
tion for day of cycle.
In conclusion, supplementation using traditional soy foods may
reduce serum oestradiol levels. Results from this and previous
studies suggest that differences in the type of soy products (i.e.
traditional soy foods versus soy protein products), amount of
isoflavones, race/ethnicity of participants and variations in the
monitoring of hormone changes have contributed to the divergent
results. Larger studies of these questions are required.
ACKNOWLEDGEMENTS
This work was supported by the California Breast Cancer
Research Program (ITB-0091-L01), Special Institutional Grant
(SIG 20) from the American Cancer Society, the Susan G Komen
Breast Cancer Foundation and the Whittier Foundation. We thank
all the study participants, Phuong Nguyen and Lydia Tran for their
help with data collection and Dr Jean Hankin for her advice.
REFERENCES
Adlercreutz H (1990) Western diet and western disease: some hormonal and
biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 50:
3–23
Adlercreutz H, Honjo A, Higashi A, Fotsis T, Hamalainen E, Hasegawa T and
Okada H (1991) Urinary excretion of lignans and isoflavonoid phytoestrogens
in Japanese men and women consuming a traditional Japanese diet. Am J Clin
Nutr 54: 1093–1100
Adlercreutz H, Mousavi Y and Hockerstedt K (1992) Diet and breast cancer. Acta
Oncol 31: 175–181
Anderson JW, Johnstone BM and Cook-Newell ME (1995) Meta-analysis of the
effects of soy protein intake on serum lipids. N Engl J Med 333: 276–282
Brown JP (1988) Hydrolysis of glycosides and esters. In: Role of the Gut Flora in
Toxicity and Cancer, Rowland IR (ed), pp. 109–144. Academic Press: San
Diego, CA
Cassidy A, Bingham S and Setchell KDR (1994) Biological effects of a diet of soy
protein rich in isoflavones on the menstrual cycle of premenopausal women.
Am J Clin Nutr 60: 333–340
Cassidy A, Bingham S and Setchell (1995) Biological effects of isoflavones in
young women: importance of the chemical composition of soyabean products.
Br J Nutr 74: 587–601
Chen Z, Zheng W, Custer LJ, Dai Q, Xhu XO, Jin F and Franke AA (1999) Usual
dietary consumption of soy foods and its correlation with the excretion rate of
isoflavonoids in overnight urine samples among Chinese women in Shanghai.
Nutr Cancer 33: 82–87
Coward L, Barnes NC, Setchell KDR and Barnes S (1993). Genistein, daidzein, and
their b-glycoside conjugates: antitumor isoflavones in soybean foods from
American and Asian diets. J Agric Food Chem 4: 1961–1967
Duncan AM, Merz BE, Xu X, Nagel TC, Phipps WR and Kurzer MS (1999) Soy
isoflavones exert modest hormonal effects in premenopausal women. J Clin
Endocrinol Metab 84: 192–197
Franke AA, Hankin JH, Yu MC, Maskarinec G, Low SH and Custer LJ (1999)
Isoflavone levels in soy foods consumed by multiethnic populations in
Singapore and Hawaii. J Agric Food Chem 47: 977–986
Goldin BR and Gorbach SL (1994) Hormone studies and the diet and breast cancer
connection. In: Diet and Breast Cancer, American Institute for Cancer
Research, pp. 35–46. Plenum Press: New York
Israel R, Mishell DR Jr, Stone SC, Thorneycroft IH and Moyer DL (1972) Single
luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet
Gynceol 112: 1043–1046
Krupps MA, Tierney LM Jr and Jawetz E (1982) Physician’s Handbook, 20th ed.
Lange Medical Publications: CA
Lu LJW, Anderson KE, Grady JJ and Nagamani M (1996) Effects of soya
consumption for one month on steroid hormones in premenopausal women:
implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers
Prev 5: 63–70
Messina M and Barnes S (1991) The role of soy products in reducing risk of cancer.
J Natl Cancer Inst 83: 541–546
Murphy PA, Song TT, Buseman G and Barua K (1997) Isoflavones in 8 soy-based
infant formulas. J Agric Food Chem 45: 4635–4638
Murphy PA, Song TT, Buseman G, Barua K, Beecher GR, Trainer D and Holden J
(1999) Isoflavones in retail and institutional soy foods. J Agric Food Chem 47:
2697–2704
Nagata C, Kabuto M, Kurisu Y and Shimizu H (1997) Decreased serum estradiol
concentration associated with high dietary intake of soy products in
premenopausal Japanese women. Nutr Cancer 29: 228–233
Nagata C, Takatsuka N, Inaba S, Norito K and Shimizu H (1998) Effect of soymilk
consumption on serum estrogen concentrations in premenopausal Japanese
women. J Natl Cancer Inst 90: 1980–1985
Petrakis N, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M
and Coward L (1996) Stimulatory influence of soy protein isolate on breast
secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers
Prev 5: 785–794
Scott JZ, Stanczyk FZ, Goebelsmann U and Mishell Dr Jr. (1978) A 
double-antibody radioimmunoassay for serum progesterone using
progesterone-3-(O-carboxymethyl) oximino[125I]-iodohistamine as 
radioligand. Steroids 31: 393–405
Setchell KDR, Cassidy A and Bingham S (1995) Reply to AH Wu and MC Pike
(letter). Am J Clin Nutr 62: 152–153
Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA and Lobo RA
(1988) A randomized comparison of normal estradiol delivery in post-
menopausal women. Am J Obstet Gynecol 159: 1540–1546
Tew BY, Xu X, Wang HJ, Murphy PA and Hendrich S (1996) A diet high in wheat
fiber decreases the bioavailability of soybean isoflavones in a single meal fed
to women. J Nutr 126: 871–877
Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada
M and Ohno Y (1999) Dietary intake and sources of isoflavones among
Japanese. Nutr Cancer 33: 139–145
Wang HJ and Murphy PA (1994) Isoflavone content in commercial soybean foods.
J Agric Food Chem 42: 1666–1673
Wu AH and Pike MC (1995) Dietary soy protein and hormonal status in females.
(letter). Am J Clin Nutr 62: 151–152
Ovarian function and soy foods in premenopausal women 1885
British Journal of Cancer (2000) 82(11), 1879–1886 © 2000 Cancer Research CampaignXu X, Wang HJ, Murphy PA, Cook L and Hendrich S (1994) Daidzein is a more
bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 124:
825–832
Xu X, Harris KS, Wang HJ, Murphy PA and Hendrich S (1995) Bioavailability of
soybean isoflavones depends upon gut microflora in women. J Nutr 125:
2307–2315
Xu X, Duncan AM, Merz BE and Kurzer MS (1998) Effects of soy isoflavones on
estrogen and phytoestrogen metabolism in premenopausal women. Cancer
Epidemiol Biomarkers Prev 7: 1101–1108
Zhang Y, Wang GJ, Song TT, Murphy PA and Hendrich S (1999) Glycitein is a more
bioavailable isoflavone than is daidzein in humans having moderate fecal
isoflavone degradation activity. J Nutr 129: 967–962
1886 AH Wu et al
British Journal of Cancer (2000) 82(11), 1879–1886 © 2000 Cancer Research Campaign